Mary Shoemaker
Director/Board Member bei TRAWS PHARMA, INC.
Vermögen: 3 417 $ am 31.03.2024
Profil
Mary Teresa Shoemaker is an Independent Director at Traws Pharma, Inc. She previously served as the President, Chief Executive Officer & Director at Medexus Pharma, Inc. from 2018 to 2020.
Prior to that, she held the position of Senior Director-Commercial Operations at Pharmion Corp.
She also worked as the Vice President-Sales at InterMune, Inc. from 2009 to 2010 and as the President-United States Operations at Medexus Pharmaceuticals, Inc. Ms. Shoemaker holds a graduate degree from the University of Central Missouri and an undergraduate degree from Missouri State University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
TRAWS PHARMA, INC.
0,02% | 10.08.2023 | 3 383 ( 0,02% ) | 3 417 $ | 31.03.2024 |
Aktive Positionen von Mary Shoemaker
| Unternehmen | Position | Beginn |
|---|---|---|
| TRAWS PHARMA, INC. | Director/Board Member | 01.04.2020 |
Ehemalige bekannte Positionen von Mary Shoemaker
| Unternehmen | Position | Ende |
|---|---|---|
| MEDEXUS PHARMACEUTICALS INC. | Corporate Officer/Principal | 22.05.2020 |
Medexus Pharma, Inc.
 Medexus Pharma, Inc. Pharmaceuticals: MajorHealth Technology Medexus Pharma, Inc. develops treatments for autoimmune diseases. It focuses on development and commercialization of treatments for autoimmune diseases as well as cancer. The company was founded in 2012 and is headquartered in Chicago, IL. | Chief Executive Officer | 01.05.2020 |
| INTERMUNE INC | Sales & Marketing | 01.07.2010 |
Pharmion Corp.
 Pharmion Corp. Pharmaceuticals: MajorHealth Technology Pharmion Corp. engages in the development and commercialization of products for the treatment of hematology and oncology patients. It has operations in Switzerland, Israel, and Philippines. The company was founded by Patrick J. Mahaffy in 1999 and is headquartered in Boulder, CO. | Corporate Officer/Principal | - |
Ausbildung von Mary Shoemaker
| University of Central Missouri | Graduate Degree |
| Missouri State University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| TRAWS PHARMA, INC. | Health Technology |
| MEDEXUS PHARMACEUTICALS INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
InterMune, Inc.
 InterMune, Inc. BiotechnologyHealth Technology InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Pharmion Corp.
Pharmion Corp. Pharmaceuticals: MajorHealth Technology Pharmion Corp. engages in the development and commercialization of products for the treatment of hematology and oncology patients. It has operations in Switzerland, Israel, and Philippines. The company was founded by Patrick J. Mahaffy in 1999 and is headquartered in Boulder, CO. | Health Technology |
Medexus Pharma, Inc.
Medexus Pharma, Inc. Pharmaceuticals: MajorHealth Technology Medexus Pharma, Inc. develops treatments for autoimmune diseases. It focuses on development and commercialization of treatments for autoimmune diseases as well as cancer. The company was founded in 2012 and is headquartered in Chicago, IL. | Health Technology |
